Bharat Parenterals Ltd vs Rekvina Labs Ltd Stock Comparison
Bharat Parenterals Ltd vs Rekvina Labs Ltd Stock Comparison
Last Updated on: Jun 14, 2026
Key Highlights
The Latest Trading Price of Bharat Parenterals Ltd is ₹ 1331 as of 12 Jun 15:30
. The P/E Ratio of Bharat Parenterals Ltd changed from 9.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Rekvina Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bharat Parenterals Ltd changed from ₹ 192 crore on March 2021 to ₹ 680.55 crore on March 2025 . This represents a CAGR of 28.80% over 5 yearsThe Market Cap of Rekvina Labs Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Bharat Parenterals Ltd for the Mar '26 is ₹ 103.25 crore as compare to the Dec '25 revenue of ₹ 66.52 crore. This represent the growth of 55.22% The revenue of Rekvina Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Bharat Parenterals Ltd for the Mar '26 is ₹ 3.1 crore as compare to the Dec '25 ebitda of ₹ 3.07 crore. This represent the growth of 0.98% The ebitda of Rekvina Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Bharat Parenterals Ltd changed from ₹ -8.84 crore to ₹ -8.16 crore over 8 quarters. This represents a CAGR of -3.92%
The net profit of Rekvina Labs Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.6 % on March 2025 . This represents a CAGR of 13.46% over 3 yearsThe Dividend Payout of Rekvina Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Bharat Parenterals Ltd
Bharat Parenterals Limited was incorporated in September, 1992 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics.
In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company on 09 July, 2016.
Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective from 28th June, 2022.
About Rekvina Labs Ltd
Rekvina Labs Limited was incorporated on 1st November 1988.
From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore.
It is registered in England and Wales as a Public Limited Company.
The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements.
It provide contract research and manufacturing services to customers.
The Company is mainly engaged in manufacturing and marketing of pharmaceutical products.
FAQs for the comparison of Bharat Parenterals Ltd and Rekvina Labs Ltd
Which company has a larger market capitalization, Bharat Parenterals Ltd or Rekvina Labs Ltd?
Market cap of Bharat Parenterals Ltd is 917 Cr while Market cap of Rekvina Labs Ltd is 23 Cr
What are the key factors driving the stock performance of Bharat Parenterals Ltd and Rekvina Labs Ltd?
The stock performance of Bharat Parenterals Ltd and Rekvina Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bharat Parenterals Ltd and Rekvina Labs Ltd?
As of June 14, 2026, the Bharat Parenterals Ltd stock price is INR ₹1331.85. On the other hand, Rekvina Labs Ltd stock price is INR ₹39.0.
How do dividend payouts of Bharat Parenterals Ltd and Rekvina Labs Ltd compare?
To compare the dividend payouts of Bharat Parenterals Ltd and Rekvina Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.